Semaglutide (Wegovy) is approved by Health Canada for chronic weight management in adults with obesity or overweight with a weight-related health condition. In Alberta, a prescribing pharmacist can initiate this treatment without a specialist referral, making GLP-1 weight management more accessible than many patients realise.
What is semaglutide, and how does it work for weight management?
Semaglutide belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists. Originally developed for type 2 diabetes, higher-dose formulations were later studied and approved specifically for chronic weight management.
GLP-1 is a hormone produced naturally in the gut after eating. Semaglutide mimics this hormone by binding to GLP-1 receptors in the brain and gut, slowing gastric emptying (so food leaves the stomach more slowly), reducing appetite signals in the brain, and producing a feeling of fullness after smaller amounts of food.
In Canada, two forms of semaglutide are approved for different indications:
- Semaglutide (Ozempic): approved by Health Canada for the management of type 2 diabetes in adults
- Semaglutide (Wegovy): approved by Health Canada for chronic weight management in adults with obesity, or adults who are overweight with at least one weight-related health condition
These are the same molecule at different doses. Ozempic reaches a maximum approved dose of 2 mg weekly. Wegovy reaches a maximum dose of 2.4 mg weekly. Using Ozempic for weight management in a person without type 2 diabetes is an off-label use that Health Canada has not approved for that indication.
Health Canada approval: what Wegovy is approved for in Canada
Health Canada approved semaglutide (Wegovy) 2.4 mg for chronic weight management in adults in 2021. The approval applies to adults who meet one of two criteria:
- Body mass index (BMI) of 30 kg/m² or higher (classified as obesity), or
- Body mass index of 27 kg/m² or higher (classified as overweight) with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea
Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity. It is not approved as a standalone treatment and the prescribing information emphasises that lifestyle modification is part of the treatment approach.
Source: Health Canada Drug Product Database.
What the clinical evidence shows: the STEP trials
The clinical trial programme supporting Health Canada's approval is called STEP (Semaglutide Treatment Effect in People with obesity). The pivotal trial, STEP-1, was published in the New England Journal of Medicine in 2021 by Wilding and colleagues.
In STEP-1, 1,961 adults with obesity or overweight (without type 2 diabetes) were randomised to receive either semaglutide 2.4 mg weekly or placebo, alongside lifestyle counselling, for 68 weeks. Results from Wilding et al., NEJM, 2021:
- The semaglutide group lost an average of 14.9% of body weight; the placebo group lost 2.4%
- 69.1% of semaglutide participants achieved at least 10% weight loss, versus 12.0% in the placebo group
- 50.5% of semaglutide participants achieved at least 15% weight loss, versus 4.9% in the placebo group
A separate trial, STEP-4, examined what happens when semaglutide is discontinued after 20 weeks of treatment. Participants who stopped the medication regained a substantial portion of their lost weight within one year, underscoring that this is a long-term treatment rather than a short course.
The Obesity Canada 2020 Canadian Adult Obesity Clinical Practice Guidelines support the use of anti-obesity medications, including GLP-1 receptor agonists, as part of a comprehensive weight management approach that includes behavioural interventions.
Who is a candidate for semaglutide weight management in Canada?
Based on Health Canada's approved indication and the Obesity Canada clinical practice guidelines, semaglutide (Wegovy) may be appropriate for adults who:
- Have a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with a weight-related health condition
- Have not achieved adequate weight loss through diet and exercise alone
- Do not have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), which are contraindications for all GLP-1 receptor agonists
- Are not pregnant or planning to become pregnant during treatment
According to Statistics Canada, approximately 26.8% of Canadian adults aged 18 to 79 were classified as obese based on directly measured BMI. Overweight rates are higher still, meaning a significant proportion of Canadians may meet the eligibility threshold for Wegovy.
A prescribing pharmacist or physician can assess your specific situation, review your medications and medical history, and determine whether semaglutide is appropriate for you.
Alberta coverage and cost: is Wegovy covered by Alberta Blue Cross?
Coverage for semaglutide (Wegovy) for weight management in Alberta is limited. Alberta Blue Cross does not currently list Wegovy as a covered benefit on its standard formulary for individuals without type 2 diabetes. This means most patients pay out of pocket.
The retail cost for Wegovy in Canada is approximately $300 to $400 per month at the maintenance dose, depending on pharmacy and dose tier. Some private employer insurance plans may provide partial coverage; this varies significantly by plan. Check with your benefits provider.
If cost is a barrier, ask a pharmacist about:
- The Novo Nordisk patient support programme for Wegovy, which may offer cost assistance for eligible patients
- Combination approaches that pair lifestyle programmes with other evidence-based options
Note that Alberta Blue Cross does cover semaglutide (Ozempic) for eligible patients with type 2 diabetes under certain benefit categories. Coverage for the weight management indication is a separate question and currently limited.
GLP-1 weight management at Acme Drug Mart in Edmonton
In Alberta, pharmacists with additional prescribing authority can initiate and manage GLP-1 therapy directly. You do not need to wait for a physician referral to access a GLP-1 weight management programme.
At Acme Drug Mart in Meadowlark, West Edmonton, our prescribing pharmacist can:
- Review your medical history and current medications for interactions and contraindications
- Confirm your eligibility based on Health Canada's approved criteria
- Start your prescription and explain the dose escalation schedule
- Monitor your progress and manage side effects through the titration period
- Advise on dietary and lifestyle approaches alongside medication
The most common side effects of semaglutide are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. These tend to be most pronounced during dose escalation (roughly the first 16 weeks) and typically improve over time. Slow titration, taking the injection with food, and staying well hydrated all help reduce the severity of these effects.
Book a GLP-1 consultation with our prescribing pharmacist at Acme Drug Mart in Meadowlark, Edmonton. We can assess your eligibility, start your prescription, and support your weight management plan without a specialist wait. Contact us to book your consultation.
Obesity in Alberta: why this matters locally
Obesity affects a significant portion of Albertans. According to Statistics Canada's Canadian Health Measures Survey, roughly 26.8% of Canadian adults aged 18 to 79 had obesity based on directly measured BMI, with overweight rates adding further to this group. Alberta's rates mirror or exceed the national average.
The Obesity Canada 2020 Canadian Adult Obesity Clinical Practice Guidelines describe obesity as a chronic disease requiring long-term management, not a lifestyle choice or a failure of willpower. The guidelines explicitly recommend pharmacotherapy, including GLP-1 receptor agonists, for patients who have not achieved adequate outcomes through lifestyle interventions alone.
Despite this, access to obesity treatment in Alberta has historically been limited by long specialist waitlists and low public awareness that pharmacist prescribing is available. Pharmacist-initiated GLP-1 programmes help close this gap.
Managing side effects: what to expect during dose escalation
Gastrointestinal side effects are the most common reason patients struggle with or discontinue semaglutide during the dose escalation phase. Understanding what is normal, what passes, and what warrants a call to your pharmacist makes the first several months more manageable.
What is common:
- Nausea (most common, especially in the first four to eight weeks at each new dose)
- Vomiting
- Diarrhoea
- Constipation
- Reduced appetite (this is expected and part of the mechanism)
Practical strategies that help:
- Take the injection on the same day each week, at a consistent time
- Eat smaller, lower-fat meals; avoid rich or greasy foods during the titration phase
- Stay well hydrated
- If nausea is significant, ask your pharmacist about delaying the dose increase by an additional four weeks
When to contact your pharmacist or physician:
- Persistent vomiting that prevents oral hydration
- Severe abdominal pain (pancreatitis is a rare but serious side effect; seek immediate care)
- Signs of low blood sugar if you are also taking insulin or a sulfonylurea
Most patients find that side effects significantly improve after the first few months at any given dose. The slow titration schedule exists precisely to reduce these effects. Do not stop semaglutide without first speaking with your prescribing pharmacist or physician, as there are usually strategies to manage side effects rather than discontinue treatment.
Frequently asked questions
Is Ozempic the same as Wegovy?
Ozempic and Wegovy both contain semaglutide, but are approved for different indications at different doses. Ozempic (up to 2 mg weekly) is approved by Health Canada for type 2 diabetes management. Wegovy (up to 2.4 mg weekly) is approved for chronic weight management. Using Ozempic for weight management in a person without type 2 diabetes is off-label use that Health Canada has not approved for that indication.
Can a pharmacist prescribe Wegovy in Alberta?
Yes. Alberta pharmacists with additional prescribing authority can initiate and manage GLP-1 therapy, including semaglutide (Wegovy), for eligible patients. You do not need a physician referral to start a pharmacist-led GLP-1 programme at a pharmacy such as Acme Drug Mart in Edmonton.
Is Wegovy covered by Alberta Blue Cross?
Semaglutide (Wegovy) for weight management is not currently listed on the Alberta Blue Cross standard formulary for individuals without type 2 diabetes. Most patients pay out of pocket, with costs roughly $300 to $400 per month at the maintenance dose. Some private insurance plans may provide partial coverage; check with your plan administrator.
How long do you need to take semaglutide for weight management?
The STEP-4 trial found that stopping semaglutide resulted in significant weight regain within one year of discontinuation. Most clinical guidelines, including the Obesity Canada 2020 guidelines, describe pharmacotherapy for obesity as a long-term treatment. Your prescribing pharmacist or physician can discuss the appropriate duration for your goals and health situation.
What is the dose escalation schedule for semaglutide (Wegovy) in Canada?
The standard Canadian schedule starts at 0.25 mg weekly for four weeks, then increases every four weeks: 0.5 mg, then 1.0 mg, then 1.7 mg, reaching the maintenance dose of 2.4 mg weekly at approximately week 17. Slower titration is used when gastrointestinal side effects are significant. Never adjust your dose without guidance from your prescribing pharmacist or physician.
This article is for informational purposes only and does not constitute medical or pharmaceutical advice. Consult your pharmacist or healthcare provider before making changes to your medications, supplements, or health routine. In a medical emergency, call 911 or go to your nearest emergency department. Consult your Acme Drug Mart pharmacist or healthcare provider before starting any new medication or supplement.
Sources
- Health Canada. Drug Product Database: semaglutide (Wegovy). Health Canada, 2021. canada.ca
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021;384:989-1002. nejm.org
- Rubino D, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4)." JAMA, 2021;325(14):1414-1425.
- Obesity Canada. "Canadian Adult Obesity Clinical Practice Guidelines." 2020. obesitycanada.ca
- Statistics Canada. "Overweight and obese adults, 2018." Health Fact Sheets, 2019. statcan.gc.ca